JPH11515025A5 - - Google Patents

Info

Publication number
JPH11515025A5
JPH11515025A5 JP1997517342A JP51734297A JPH11515025A5 JP H11515025 A5 JPH11515025 A5 JP H11515025A5 JP 1997517342 A JP1997517342 A JP 1997517342A JP 51734297 A JP51734297 A JP 51734297A JP H11515025 A5 JPH11515025 A5 JP H11515025A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997517342A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11515025A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1996/015854 external-priority patent/WO1997016184A1/en
Publication of JPH11515025A publication Critical patent/JPH11515025A/ja
Publication of JPH11515025A5 publication Critical patent/JPH11515025A5/ja
Ceased legal-status Critical Current

Links

JP9517342A 1995-11-02 1996-10-02 脂質濃度を調節するための方法および医薬組成物 Ceased JPH11515025A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US615595P 1995-11-02 1995-11-02
US60/006,155 1995-11-02
PCT/US1996/015854 WO1997016184A1 (en) 1995-11-02 1996-10-02 Method and pharmaceutical composition for regulating lipid concentration

Publications (2)

Publication Number Publication Date
JPH11515025A JPH11515025A (ja) 1999-12-21
JPH11515025A5 true JPH11515025A5 (2) 2004-10-21

Family

ID=21719566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9517342A Ceased JPH11515025A (ja) 1995-11-02 1996-10-02 脂質濃度を調節するための方法および医薬組成物

Country Status (26)

Country Link
US (3) US6124309A (2)
EP (1) EP0858336B1 (2)
JP (1) JPH11515025A (2)
KR (2) KR100449604B1 (2)
CN (2) CN1679953A (2)
AR (1) AR004527A1 (2)
AT (1) ATE348607T1 (2)
AU (1) AU720853B2 (2)
BG (1) BG64018B1 (2)
BR (1) BR9611410A (2)
CZ (1) CZ127198A3 (2)
DE (1) DE69636783T2 (2)
EA (1) EA000514B1 (2)
ES (1) ES2279526T3 (2)
GE (1) GEP20001898B (2)
HU (1) HUP9901865A3 (2)
IL (1) IL123902A (2)
IS (1) IS4720A (2)
NO (1) NO981961L (2)
NZ (2) NZ512484A (2)
PL (1) PL186714B1 (2)
RO (1) RO120816B1 (2)
SK (1) SK284142B6 (2)
UA (1) UA46069C2 (2)
WO (1) WO1997016184A1 (2)
ZA (1) ZA969187B (2)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
EP1514543A1 (en) * 1997-08-29 2005-03-16 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
EP1063991A1 (en) * 1998-03-17 2001-01-03 Warner-Lambert Company Llc Statin-matrix metalloproteinase inhibitor combinations
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
YU23901A (sh) * 1998-09-30 2003-07-07 Warner-Lambert Company Upotreba sredstva za snižavanje holesterola u sprečavanju i odlaganju revaskularizacije pomoću katetera
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
WO2001022962A1 (en) * 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
EP1092432A1 (fr) * 1999-10-15 2001-04-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Composes anti-ischemiques
HUP0203160A3 (en) * 1999-11-05 2006-02-28 Warner Lambert Co Prevention of plaque rupture by acat inhibitors
WO2002020009A1 (en) * 2000-09-01 2002-03-14 Sankyo Company, Limited Medicinal compositions
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
CA2425311C (en) 2000-10-11 2011-06-14 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
JP2004531459A (ja) 2000-10-11 2004-10-14 エスペリオン セラピューティクス，インコーポレイテッド コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
CN101426763A (zh) 2000-10-11 2009-05-06 埃斯佩里安医疗公司 用于胆固醇治疗和相关应用的硫化物和二硫化物化合物和组合物
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CN1894195A (zh) 2000-10-11 2007-01-10 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的醚化合物以及组合物
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US20050020694A1 (en) * 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US20040192771A1 (en) * 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
CA2478184A1 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Drug combination therapy
JP2005522504A (ja) * 2002-04-10 2005-07-28 エスペリオン セラピューティクス，インコーポレイテッド パントラクトンおよびパントテン酸誘導体を含むアシル補酵素−ａのミミック、その組成物、ならびにコレステロール管理の方法および関連の使用
JP4187141B2 (ja) * 2002-04-12 2008-11-26 興和株式会社 新規なトロンボモジュリン発現促進剤
ES2625429T3 (es) * 2003-01-23 2017-07-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
KR20060111898A (ko) 2003-08-29 2006-10-30 교와 가부시키가이샤 지질-풍부-플라크의 안정화 방법 및 파열 예방방법
JPWO2005046706A1 (ja) * 2003-11-17 2007-05-31 株式会社東洋新薬 松樹皮抽出物を含む脂質代謝改善剤
JP2007525408A (ja) 2003-12-24 2007-09-06 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理および関連使用のためのケトン化合物および組成物
US20050234068A1 (en) * 2004-04-19 2005-10-20 Baldwin Dalton D Composition and method of decreasing renal ischemic damage
TW200605890A (en) * 2004-07-28 2006-02-16 Sankyo Co Pharmaceutical compositions for inhibiting arteriosclerosis
TW200619191A (en) * 2004-10-27 2006-06-16 Sankyo Co Phenyl compounds with more than 2 substitutes
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
RU2308947C1 (ru) * 2006-02-26 2007-10-27 Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН) Лекарственное средство с гиполипидемическим эффектом "симваглизин"
US9597289B2 (en) 2006-04-26 2017-03-21 Rosemont Pharmaceuticals Ltd. Liquid oral simvastatin compositions
US20130254787A1 (en) 2006-05-02 2013-09-26 Invidi Technologies Corporation Method and apparatus to perform real-time audience estimation and commercial selection suitable for targeted advertising
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
US8314080B2 (en) 2010-04-06 2012-11-20 Kuwait University Method of treating type I diabetes
CN103274985B (zh) * 2010-12-03 2016-03-09 上海科州药物研发有限公司 一种阿托伐他汀氨基酸盐
US8586527B2 (en) * 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
CN103304496A (zh) * 2012-03-08 2013-09-18 南京工业大学 一种合成申嗪霉素方法
US10047034B2 (en) 2012-05-16 2018-08-14 Prairie Berry Europe Gmbh Polyhydroxylated pentacyclic triterpene acids as HMG-COA reductase inhibitors
EP3267989A4 (en) 2015-03-13 2018-11-07 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
MX2021015936A (es) 2019-06-21 2022-04-26 Esperion Therapeutics Inc Metodos para preparar acido bempedoico y composiciones del mismo.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2048395A1 (en) * 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
JP2525125B2 (ja) 1991-07-23 1996-08-14 シェリング・コーポレーション 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法
AU5538794A (en) * 1992-10-26 1994-05-24 Merck & Co., Inc. Biologically active compounds and process therefor
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
AU1095695A (en) * 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration

Similar Documents

Publication Publication Date Title
JP2000500445A5 (2)
JP2000500033A5 (2)
JP2000500440A5 (2)
JP2000502264A5 (2)
JP2000500327A5 (2)
JP2000500145A5 (2)
JP2000500155A5 (2)
JP2000505208A5 (2)
JP2000500406A5 (2)
JP2000500361A5 (2)
JP2000500115A5 (2)
JP2000503193A5 (2)
JPH11512191A5 (2)
JP2000500322A5 (2)
JPH11515025A5 (2)
JPH11507763A5 (2)
JP2000500342A5 (2)
JPH11510479A5 (2)
JP2000500112A5 (2)
JP2000500051A5 (2)
JP2000500407A5 (2)
JP2000500397A5 (2)
JP2000500019A5 (2)
JPH11508866A5 (2)
JP2000500125A5 (2)